Eating

11 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
famotidine	DR REDDYS LABORATORIES LTD (RDY)
lisdexamfetamine di	Amneal Pharmaceuticals, Inc. (AMRX)
lisdexamfetamine di	Mylan II B.V. (MYL)
lisdexamfetamine di	ELITE PHARMACEUTICALS INC /NV/ (ELTP)

Phase 1(1)

Drug	Company
lira-cel	Anixa Biosciences Inc (ANIX)

Preclinical(2)

Drug	Company
Other ecDTx programs (preclinical or discovery stage)	Boundless Bio, Inc. (BOLD)
psilocybin	Kaya Holdings, Inc. (KAYS)

Unknown(2)

Drug	Company
iPScelz™ (iPSC program)	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Medical formulations portfolio	Cannabis Bioscience International Holdings, Inc. (CBIH)

N/A(2)

Drug	Company
ecDTx (ecDNA directed therapeutic candidates)	Boundless Bio, Inc. (BOLD)
Unnamed ecDTx (one in clinical development)	Boundless Bio, Inc. (BOLD)

BioSniper tracks 11 drugs in development for Eating across 9 companies.

There are 1 clinical trial targeting Eating tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.